Selected article for: "fusion function and virus entry"

Author: Cosset, François-Loic; Lavillette, Dimitri
Title: Cell Entry of Enveloped Viruses
  • Cord-id: vo6j8zb0
  • Document date: 2011_2_8
  • ID: vo6j8zb0
    Snippet: Enveloped viruses penetrate their cell targets following the merging of their membrane with that of the cell. This fusion process is catalyzed by one or several viral glycoproteins incorporated on the membrane of the virus. These envelope glycoproteins (EnvGP) evolved in order to combine two features. First, they acquired a domain to bind to a specific cellular protein, named “receptor.” Second, they developed, with the help of cellular proteins, a function of finely controlled fusion to opt
    Document: Enveloped viruses penetrate their cell targets following the merging of their membrane with that of the cell. This fusion process is catalyzed by one or several viral glycoproteins incorporated on the membrane of the virus. These envelope glycoproteins (EnvGP) evolved in order to combine two features. First, they acquired a domain to bind to a specific cellular protein, named “receptor.” Second, they developed, with the help of cellular proteins, a function of finely controlled fusion to optimize the replication and preserve the integrity of the cell, specific to the genus of the virus. Following the activation of the EnvGP either by binding to their receptors and/or sometimes the acid pH of the endosomes, many changes of conformation permit ultimately the action of a specific hydrophobic domain, the fusion peptide, which destabilizes the cell membrane and leads to the opening of the lipidic membrane. The comprehension of these mechanisms is essential to develop medicines of the therapeutic class of entry inhibitor like enfuvirtide (Fuzeon) against human immunodeficiency virus (HIV). In this chapter, we will summarize the different envelope glycoprotein structures that viruses develop to achieve membrane fusion and the entry of the virus. We will describe the different entry pathways and cellular proteins that viruses have subverted to allow infection of the cell and the receptors that are used. Finally, we will illustrate more precisely the recent discoveries that have been made within the field of the entry process, with a focus on the use of pseudoparticles. These pseudoparticles are suitable for high-throughput screenings that help in the development of natural or artificial inhibitors as new therapeutics of the class of entry inhibitors.

    Search related documents:
    Co phrase search for related documents
    • active form and addition time: 1, 2
    • active form and addition time experiment: 1
    • acute sars cov respiratory syndrome coronavirus and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and additional level: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and additional mechanism: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and additional role: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and adenovirus receptor: 1, 2
    • acute sars cov respiratory syndrome coronavirus and liver cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute sars cov respiratory syndrome coronavirus and liver cell line: 1
    • acute sars cov respiratory syndrome coronavirus and liver cell line cell: 1
    • acute sars cov respiratory syndrome coronavirus and long terminal repeat: 1
    • acute sars cov respiratory syndrome coronavirus and low density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute sars cov respiratory syndrome coronavirus and low density ldlr lipoprotein receptor: 1
    • acute sars cov respiratory syndrome coronavirus and low ph dependent: 1
    • acute sars cov respiratory syndrome coronavirus and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute sars cov respiratory syndrome coronavirus and lymphocytic choriomeningitis: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and lymphocytic choriomeningitis arenavirus: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lysosomal protease: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and lysosomotropic agent: 1, 2, 3, 4, 5